Sellers of unapproved peptides must label them research use only, but CNN reports many may soon be allowed to drop that warning.
Recap by typeshit. Full story at CNN on MSN.
Some people on weight loss drugs are testing lower doses, hoping for fewer side effects. ThePrint reports on the trend, which these users describe themselves.
Bell raises the question of muscle loss for people losing weight on a GLP-1 and notes it isn't medical advice, pointing viewers to their doctor.
Dr. Woo points to the official position of the AAO and NANOS on whether routine eye exams just to check for NAION are needed.
USA TODAY covers the copycat GLP-1 crackdown, from the Apothecary Pharma recall to an import alert on a Chengdu factory. Novo says it has filed over 130 lawsuits.
Covers the 28.3% versus 25.0% weight loss figures, the 12% who quit at 9 mg in TRIUMPH-2, and why online vials sold as Reta aren't the trial drug.
Across nearly 44,000 matched patients over 65, GLP-1 users had a 45% lower death risk, researchers report, though they also saw more osteoporosis and retinopathy.
Loading…